Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
Currently, dual antiplatelet therapy with aspirin and clopidogrel (with loading doses) is
widely used for patients with acute ischemic stroke. However, immediate, potent and
reversible inhibition of platelet aggregation is not possible. Additionally, more than 5%
patients have aspirin resistance and more than 15% patients have clopidogrel resistance.
Therefore, an intravenously administered GPIIb/IIIa receptor inhibitor (Tirofiban) receptor
blocker with fast onset and offset of actions will provide more desired antiplatelet effects
in the setting of acute ischemic stroke, especially in patients with high risk of
neurological deterioration. This study will measure the anti-platelet effects of Tirofiban in
patients with acute ischemic stroke who had high risk of neurological deterioration.